IFNB1 and myeloid sarcoma: The study shows that the distribution of adaptive NK cell markers in MS may vary not only depending on HCMV seropositivity but also on IFNβ therapy and disease form, revealing differences in their antibody-dependent activation as compared to healthy individuals.